Addressing hypersensitivity reactions induced by Daratumumab: A review of management approaches and preventive measures

Abstract

Daratumumab is a novel and remedial monoclonal antibody with broad-spectrum killing activity. It has shown a favorable safety profile as monotherapy in cases with relapsed/refractory multiple myeloma. Daratumumab along with its remedial benefits is associated with a range of Adverse Drug Reactions (ADRs) most importantly Hypersensitivity reactions that can significantly impact patient outcomes and health-related quality of life. The standard of care can be maintained by administering pre-infusion prophylactic medications and also by optimizing the Daratumumab infusions. The review focuses on the adverse drug reactions induced by Daratumumab, various preventative measures, and management strategies opted for curbing the Daratumumab-mediated infusion-related hypersensitivity reactions.